October 1, 2020 — VLP Therapeutics Japan, LLC (VLPTJ) announced on today that VLPTJ signed a contract manufacturing agreement with FUJIFILM Corporation (FUJIFILM) for a novel coronavirus (COVID-19) vaccine formulation developed by VLPTJ.

This self-amplifying (replicon) RNA vaccine employs a platform technology proprietary to VLP Therapeutics, LLC, the US-based wholly owning parent company of VLPTJ. It is a second-generation product that possesses a high level of safety with efficient induction of protective immunity.

FUJIFILM will be responsible for contract manufacturing lipid nanoparticle formulations containing replicon RNA, which is an active ingredient of VLPTJ’s vaccine.

This COVID-19 vaccine R&D project is among those selected for funding in August by the Japan Agency for Medical Research and Development (AMED). VLPTJ will proceed in Japan with pre-clinical and clinical trials of the vaccine in collaboration with the National Center for Global Health and Medicine; the National Institutes of Biomedical Innovation, Health and Nutrition; Oita University; and Osaka City University.

This newly-forged alliance with FUJIFILM is expected to make it possible to manufacture the COVID-19 vaccine in an expedited, stable fashion.

About VLP Therapeutics Japan, LLC (VLPTJ)

VLPTJ is a wholly-owned subsidiary of US-based vaccine research and development company VLP Therapeutics, LLC, established in 2013 and headquartered in Gaithersburg, Maryland. For further details please see: https://vlptherapeutics.co.jp/

Media contact: info@vlptherapeutics.co.jp